Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia.

ABSTRACT: Minimal (or measurable) residual (MRD) disease provides a biomarker of response quality for which there is robust validation in the context of modern intensive treatment for younger patients with Acute Myeloid Leukemia (AML). Nevertheless, it remains a relatively unexplored area in older patients with AML. The lack of progress in this field can be attributed to two main reasons. First, physicians have a general reluctance to submitting older adults to intensive chemotherapy due to their frailty and to the unfavourable biological disease profile predicting a poor outcome following conventional chemotherapy. Second, with the increasing use of low-intensity therapies (i.e., hypomethylating agents) differing from conventional drugs in mechanism of action and dynamics of response, there has bee

SUBMITTER: Buccisano F 

PROVIDER: S-EPMC6070940 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature